Skip to the answer

Abacavir, Dolutegravir, and Lamivudine Uses, Dosage, Side Effects and Interactions

Brand names
Triumeq

Triumeq was approved by the FDA in August 2014 as a tablet. No generic is listed as tablets.

First generic of Triumeq: our estimate, sometime in 2028

Triumeq PD

Triumeq PD was approved by the FDA in March 2022 as a tablet. No generic is listed as tablets.

First generic of Triumeq PD: our estimate, sometime in 2028

Abacavir, dolutegravir, and lamivudine is a three-drug combination used to treat HIV-1 infection in adults and in children aged at least 3 months who weigh at least 6 kg.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Abacavir, Dolutegravir, and LamivudineType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Abacavir, Dolutegravir, and Lamivudine in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Triumeq is a complete HIV-1 treatment in one tablet, pairing dolutegravir, which keeps HIV from inserting itself into your cells, with abacavir and lamivudine, which block the enzyme HIV uses to copy itself; on the market for over a decade and not available generically, it is a well-established choice for people without the HLA-B*5701 gene. Most people tolerate it well; trouble sleeping, headache and tiredness are what they notice most. Its main boxed warning is a serious, sometimes fatal allergic reaction to abacavir, usually in the first 6 weeks, with fever, rash, vomiting, diarrhea, cough or feeling very unwell; stop it, get help right away, and never restart it.

Key Takeaways From the HelloPharmacist Team

  • Take it once a day, with or without food, and avoid skipping doses, because missed doses give HIV a chance to become resistant.
  • If it keeps you awake, taking it in the morning often helps, and trouble sleeping and headaches tend to ease over the first few weeks.
  • Never stop it on your own if you have hepatitis B, because stopping can set off a severe flare that damages the liver.
  • Never combine it with dofetilide, a heart rhythm medicine, and expect your prescriber to recheck your metformin dose, since dolutegravir can raise metformin levels.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Abacavir, Dolutegravir, and Lamivudine.

Serious, sometimes fatal allergic reactions can happen with the abacavir in this medicine. They can affect several parts of the body at once. Your risk is higher if you carry the HLA-B*5701 gene, so you should be tested before you start.

If you may be having a reaction, stop the medicine right away and get medical help. Never restart it, or any abacavir-containing medicine, after a reaction. Symptoms can return more severely within hours.

This medicine also carries a risk for people with hepatitis B. You should be tested before starting. Lamivudine-resistant hepatitis B has been reported, and severe flare-ups of hepatitis B can occur if you stop this medicine. Your liver should be closely monitored if that happens.

Read the full warning on DailyMed →

Abacavir, Dolutegravir, and Lamivudine by the Numbers

Strengths
2
in one form
Makers and packagers
1
Earliest FDA record
2010
Rank by Medicaid prescriptions
#641 of 1,682 drugs
More prescriptions than 61% of the 1,682 drugs we measure
51,277 prescriptions, Q1–Q4 2025

Patient Information Guide for Abacavir, Dolutegravir, and Lamivudine

What It’s Used For

This three-drug combination treats HIV-1 infection.

  • Triumeq and Triumeq PD treat HIV-1 infection in adults.
  • They are also used in pediatric patients aged at least 3 months who weigh at least 6 kg.
  • They are not recommended alone if integrase inhibitor resistance is present or suspected.

How It Works

Dolutegravir is an integrase strand transfer inhibitor (INSTI). Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors. Together they attack HIV-1 at more than one step.

Because the dolutegravir dose in this combination is fixed, it is not enough if integrase inhibitor resistance is present.

Drug Class

Drug Class

  • Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor from dolutegravir
  • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from abacavir
  • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine
  • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Abacavir, Dolutegravir, and Lamivudine has three active ingredients, so each class says which one it comes from.

Drug Class

Established Pharmacologic Class (EPC)
  • Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor from dolutegravir
  • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from abacavir
  • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine
  • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • HIV Integrase Inhibitors from dolutegravir
  • Organic Cation Transporter 2 Inhibitors from dolutegravir
  • Multidrug and Toxin Extrusion Transporter 1 Inhibitors from dolutegravir
  • Nucleoside Reverse Transcriptase Inhibitors from abacavir
  • Cytochrome P450 1A1 Inhibitors from abacavir
  • Nucleoside Reverse Transcriptase Inhibitors from lamivudine

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Abacavir, Dolutegravir, and Lamivudine in the FDA’s index.

From our Patient Information GuideDolutegravir is an integrase strand transfer inhibitor (INSTI). Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors. Together they attack HIV-1 at more than one step. Read How Abacavir, Dolutegravir, and Lamivudine Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Abacavir, Dolutegravir, and Lamivudine in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Antivirals for treatment of HIV infections, combinations

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Triumeq is taken by mouth once daily in adults. You can take it with or without food.

  • Get tested for HLA-B*5701 and hepatitis B before starting.
  • Children's dosing depends on body weight and uses Triumeq PD tablets for some weights.
  • Triumeq and Triumeq PD are not interchangeable milligram for milligram.

Follow your prescriber and the label.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Triumeq tablets once daily

For adults
Dose 600 mg
  • One tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) once daily orally with or without food

Good to know

Do not use Triumeq PD in adults

Triumeq PD tablets

These are the doses for children. For adults, see “Triumeq tablets once daily.”

Children 6 kg to under 10 kg Usual dose 3 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
  • 3 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 180 mg ABC, 15 mg DTG, and 90 mg 3TC

Good to know

Triumeq tablets not recommended; disperse in 15 mL drinking water

Children 10 kg to under 14 kg Usual dose 4 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
  • 4 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 240 mg ABC, 20 mg DTG, and 120 mg 3TC

Good to know

Triumeq tablets not recommended; disperse in 20 mL drinking water

Children 14 kg to under 20 kg Usual dose 5 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
  • 5 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 300 mg ABC, 25 mg DTG, and 150 mg 3TC

Good to know

Triumeq tablets not recommended; disperse in 20 mL drinking water

Children 20 kg to under 25 kg Usual dose 6 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
  • 6 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 360 mg ABC, 30 mg DTG, and 180 mg 3TC

Good to know

Triumeq tablets not recommended; disperse in 20 mL drinking water

These are the doses for children. For adults, see “Triumeq tablets once daily.”

HIV-1 infection

For children weighing 25 kg or more
Usual dose 1 tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) once a day

Good to know

Triumeq PD not recommended

See the Full Dosing Instructions on DailyMed →

Side Effects

The most commonly reported side effects in people taking Triumeq were:

Common side effects

  • Trouble sleeping (insomnia)
  • Headache
  • Tiredness (fatigue)

When to get medical help

  • Stop the medicine and get medical help right away if you suspect an allergic reaction to abacavir. Signs include fever, rash, nausea, vomiting, diarrhea, stomach pain, feeling very unwell or achy, cough, shortness of breath, or sore throat.
  • Never restart this medicine, or any medicine containing abacavir, after a suspected hypersensitivity reaction. Symptoms can be worse and can lead to death within hours.
  • Tell your doctor about yellow skin or eyes, dark urine, or severe stomach pain. These can signal liver problems (hepatotoxicity).
  • Tell your doctor if hepatitis B symptoms flare after stopping this medicine, if you have hepatitis B.
  • Report symptoms of lactic acidosis (a buildup of acid in the blood) or a severely enlarged, fatty liver. These have been seen with nucleoside analogues and can be fatal.
  • Tell your doctor about new symptoms after starting HIV treatment. This may be immune reconstitution syndrome.
  • Heart attack (myocardial infarction) is listed among the reported adverse reactions, so seek emergency care for heart attack symptoms.

Warnings and Precautions

  • Abacavir hypersensitivity: can be fatal. Stop the medicine at once if you suspect it. Never restart afterward.
  • Hepatitis B: test before starting. Severe flares can occur after stopping.
  • Liver problems: liver toxicity has been reported with dolutegravir regimens, so monitoring is recommended.
  • Lactic acidosis and enlarged fatty liver: reported with nucleoside analogues, including fatal cases.
  • Immune reconstitution syndrome: reported with combination HIV treatment.
  • Heart attack: listed among reported adverse reactions.

Interactions

Tell your pharmacist about all your medicines. Key ones:

  • Dofetilide: contraindicated because levels may rise to dangerous amounts.
  • Metformin and dalfampridine: dolutegravir may raise their levels.
  • Etravirine: lowers dolutegravir and is not recommended without certain boosting partners.
  • Efavirenz: lowers dolutegravir, so extra dolutegravir may be needed.
  • Drugs that affect UGT1A1, CYP3A, or P-gp can change dolutegravir levels.

Interactions Listed in the FDA-Approved Label

From the Abacavir, Dolutegravir, and Lamivudine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin
    What happensThese drugs may decrease dolutegravir concentrations, so the dolutegravir dose in TRIUMEQ is insufficient.
    What to doIn adults and pediatric patients weighing at least 25 kg, dolutegravir 50 mg twice daily: take an additional TIVICAY 50-mg tablet 12 hours after TRIUMEQ. In patients 6 kg to <25 kg, give an additional weight-based dolutegravir dose 12 hours after TRIUMEQ PD (15 mg, 20 mg, 25 mg or 30 mg by weight band).
  • What happensDecreases dolutegravir concentrations.
    What to doUse with etravirine without atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.
  • What happensDecreases dolutegravir concentrations.
    What to doAvoid coadministration because there are insufficient data to make dosing recommendations.
  • Oxcarbazepine, phenytoin, phenobarbital, St. John's wort
    What happensDecrease dolutegravir concentrations.
    What to doAvoid coadministration because there are insufficient data to make dosing recommendations.
  • What happensIncreases dofetilide concentrations.
    What to doCoadministration is contraindicated.
  • What happensIncreases dalfampridine levels, which raise the risk of seizures.
    What to doConsider the potential benefits against the risk of seizures.
  • Cation-containing antacids or laxatives, sucralfate, buffered medications (polyvalent cations, e.g., Mg or Al)
    What happensDecrease dolutegravir concentrations.
    What to doAdminister TRIUMEQ or TRIUMEQ PD 2 hours before or 6 hours after these medications.
  • Oral calcium and iron supplements, including multivitamins containing calcium or iron
    What happensDecrease dolutegravir concentrations.
    What to doWith food, can be taken at the same time. Under fasting conditions, take TRIUMEQ 2 hours before or 6 hours after supplements.
  • What happensIncreases metformin concentrations.
    What to doRefer to the metformin prescribing information for assessing benefit and risk of concomitant use.
Read the label’s full interactions text

7 DRUG INTERACTIONS Coadministration of TRIUMEQ or TRIUMEQ PD with other drugs can alter the concentration of other drugs and other drugs may alter the concentrations of TRIUMEQ or TRIUMEQ PD. The potential drug-drug interactions must be considered prior to and during therapy. 7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents In vitro, dolutegravir inhibited the renal organic cation transporters (OCT)2 (IC 50 = 1.93 microM) and multidrug and toxin extrusion transporter (MATE)1 (IC 50 = 6.34 microM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin). In vitro, dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 (IC 50 = 2.12 microM) and OAT3 (IC 50 = 1.97 microM). However, in vivo, dolutegravir did not alter the plasma concentrations of tenofovir or para-amino hippurate, substrates of OAT1 and OAT3. In vitro, dolutegravir did not inhibit (IC 50 >50 microM) the following: cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, uridine diphosphate (UDP)-glucuronosyl transferase (UGT)1A1, UGT2B7, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, or multidrug resistance protein (MRP)2, or MRP4. In vitro, dolutegravir did not induce CYP1A2, CYP2B6, CYP3A4. Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use if you carry HLA-B*5701 or have had a prior reaction to abacavir, dolutegravir, or lamivudine.
  • Do not use with moderate or severe liver impairment.
  • Do not use with dofetilide.
  • Get tested for hepatitis B first.
  • Tell your doctor about any past use of abacavir-containing medicines.
  • Only for children aged at least 3 months and weighing at least 6 kg.

Overdose

There is no known specific treatment for overdose. You would be monitored and given standard supportive care. Dialysis is unlikely to remove much dolutegravir, and it is not known whether it helps with abacavir or lamivudine.

Half-Life and How Your Body Processes It

One Triumeq tablet was bioequivalent to dolutegravir plus an abacavir/lamivudine tablet taken separately. Abacavir is absorbed quickly and has a half-life of about 1.5 hours. Dolutegravir peaks 2 to 3 hours after a dose, reaches steady state in about 5 days, and is mostly cleared through the liver and feces, with some in urine. Triumeq PD gives about 1.7-fold higher dolutegravir than Triumeq, so they are not interchangeable.

Storage

Store and dispense in the original package, protect from moisture, and keep the bottle tightly closed. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Abacavir, Dolutegravir, and Lamivudine

From the licensed clinical database we use, rolled up per supplement, most serious first.

56 supplements and herbal products have documented interactions with Abacavir, Dolutegravir, and Lamivudine in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 4Major
  • 43Moderate
  • 9Minor

See the other 48

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Abacavir, Dolutegravir, and Lamivudine: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Abacavir, Dolutegravir, and Lamivudine — the kind of thing our pharmacy team would talk through with you at the counter.

What is this medicine for?

It treats HIV-1 infection. Triumeq combines three HIV medicines in one tablet, for adults and for children aged at least 3 months who weigh at least 6 kg.

Why did I need blood tests before starting?

Your doctor checks for the HLA-B*5701 gene because it raises the risk of a serious allergic reaction to abacavir. You are also tested for hepatitis B, since lamivudine can affect it. If you carry the gene, you should not take this medicine.

How do I take it?

Adults take one tablet by mouth once a day, with or without food. Follow your prescriber's directions and the label exactly.

What side effects are common?

The most commonly reported are trouble sleeping, headache, and tiredness. Tell your doctor if they bother you or don't go away.

What symptoms mean I should stop and call right away?

Fever, rash, nausea, vomiting, diarrhea, stomach pain, extreme tiredness or achiness, cough, or shortness of breath could signal an allergic reaction to abacavir. Stop the medicine and get medical help immediately. If this happens, you must never take it or any abacavir-containing medicine again.

Can I stop it suddenly if I have hepatitis B too?

Don't stop on your own. If you have both HIV and hepatitis B, stopping lamivudine can cause a severe hepatitis B flare. Your doctor will monitor your liver closely if you stop.

Is abacavir, dolutegravir, and lamivudine available over the counter?

No. Abacavir, dolutegravir, and lamivudine is a prescription medicine: every abacavir, dolutegravir, and lamivudine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was abacavir, dolutegravir, and lamivudine first available?

The earliest FDA record we hold for abacavir, dolutegravir, and lamivudine is from 2010: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when abacavir, dolutegravir, and lamivudine was first used.

What is the brand name of abacavir, dolutegravir, and lamivudine?

Abacavir, dolutegravir, and lamivudine is the generic name. Its brand names are Triumeq and Triumeq PD.

What is the generic name of Triumeq?

The generic name of Triumeq is abacavir, dolutegravir, and lamivudine. A generic name is the name of the active ingredients, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is abacavir, dolutegravir, and lamivudine?

Abacavir, dolutegravir, and lamivudine belongs to the drug class Hepatitis B Nucleoside Analog Reverse Transcriptase Inhibitor, HIV Nucleoside Analog Reverse Transcriptase Inhibitor and HIV Integrase Strand Transfer Inhibitor, its established pharmacologic class on the FDA label. The FDA also groups it by how it works: Organic Cation Transporter 2 Inhibitor, Multidrug and Toxin Extrusion Transporter 1 Inhibitor and CYP1A1 Enzyme Inhibitor.

What strengths does abacavir, dolutegravir, and lamivudine come in?

Abacavir, dolutegravir, and lamivudine is listed in the FDA's National Drug Code Directory in these forms and strengths. Tablet (by mouth): 300 mg and 600 mg/50 mg/300 mg. A listing does not mean every pharmacy stocks every strength.

How much does abacavir, dolutegravir, and lamivudine cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, pharmacies paid a national average of $130.09 per ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg tablet of brand-name Triumeq as of November 18, 2026 (CMS's NADAC survey). That is the pharmacy's own cost for the medicine, not the price at the counter. The pharmacy prices section of this page lists every strength priced.

Where can I read the abacavir, dolutegravir, and lamivudine prescribing information (package insert)?

The full FDA-approved prescribing information for abacavir, dolutegravir, and lamivudine, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from ViiV Healthcare Company's, revised Jul 8, 2024, and links to it on DailyMed.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Abacavir, Dolutegravir, and Lamivudine

Skip the scrolling. Ask in your own words and get an answer from Abacavir, Dolutegravir, and Lamivudine’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Abacavir, Dolutegravir, and Lamivudine’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Abacavir, Dolutegravir, and Lamivudine on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Abacavir, Dolutegravir, and Lamivudine Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Abacavir, Dolutegravir, and Lamivudine Forms and Strengths (How It Comes)

Abacavir, Dolutegravir, and Lamivudine comes in 1 dose form, the tablet. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Abacavir, Dolutegravir, and Lamivudine inactive ingredients by manufacturer.

Tablet

By mouth
Brands Triumeq (2014) Triumeq PD (2022)
How this form is used
What it may be used for
  • Triumeq treats HIV-1 infection in adults and in children aged at least 3 months and weighing at least 6 kg.
Important instructions
  • Triumeq may be taken with or without food.
  • Triumeq is taken as one tablet once daily in adults.
  • Triumeq tablets and Triumeq PD tablets for oral suspension are not substitutable milligram for milligram.
Available strengths 2 strengths
2 FDA-listed product records ⓘ

Abacavir, Dolutegravir, and Lamivudine on the U.S. Market: Products, Makers and Brands

How Abacavir, Dolutegravir, and Lamivudine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 2 Abacavir, Dolutegravir, and Lamivudine product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2010. Brand names in the directory today include Triumeq and Triumeq PD; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
2
Brand names ⓘ
2
FDA-listed product records ⓘ
2010
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Unfinished tablet, film coated (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

How Widely Abacavir, Dolutegravir, and Lamivudine Is Used (Medicaid Data)

How many Abacavir, Dolutegravir, and Lamivudine prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

51,277
Medicaid prescriptions filled (Q1–Q4 2025)
$220.7M paid by Medicaid, before rebates

How commonly is Abacavir, Dolutegravir, and Lamivudine prescribed? Of the 1,682 medications we measure, Abacavir, Dolutegravir, and Lamivudine ranks #641 by Medicaid prescriptions — more than 62% of them.

Where Abacavir, Dolutegravir, and Lamivudine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Abacavir, Dolutegravir, and Lamivudine product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 600 mg / 50 mg / 300 mg oral tablet is the most-dispensed Abacavir, Dolutegravir, and Lamivudine product — about 99% of these Medicaid prescriptions.

abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet Most dispensed

51,010 Medicaid prescriptions (Q1–Q4 2025) 99% of Abacavir, Dolutegravir, and Lamivudine prescriptions shown $220.2M paid by Medicaid, before rebates ≈ $4,317 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 1546888

abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension

267 Medicaid prescriptions (Q1–Q4 2025) <1% of Abacavir, Dolutegravir, and Lamivudine prescriptions shown $501,248 paid by Medicaid, before rebates ≈ $1,877 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2598348

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 2 of the 3 listed Abacavir, Dolutegravir, and Lamivudine NDCs had Medicaid claims.

Compare Abacavir, Dolutegravir, and Lamivudine Products

A representative set of FDA-listed product records for Abacavir, Dolutegravir, and Lamivudine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Tablet
ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg Oral ViiV Healthcare Company NDA View NDC →
💊Kits
— — ViiV Healthcare Company NDA View NDC →

Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Abacavir, Dolutegravir, and Lamivudine NDCs →

Abacavir, Dolutegravir, and Lamivudine Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Abacavir, Dolutegravir, and Lamivudine recalls since July 2021.

✅No Abacavir, Dolutegravir, and Lamivudine recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Abacavir, Dolutegravir, and Lamivudine in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one exact combination of ingredients (MIN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. A different combination is a different concept with its own page.

Dose forms
2
Strengths
2
Forms in current FDA listings
2 of 2
In current FDA listings No current FDA listing
Multiple ingredients (MIN) Abacavir, Dolutegravir, and Lamivudine RxCUI 1546887
  1. Dose form (SCDF) Oral Tablet RxCUI 1546886
    In current FDA listings
  2. Dose form (SCDF) Tablet for Oral Suspension RxCUI 2598347
    In current FDA listings

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Abacavir, Dolutegravir, and Lamivudine Costs Pharmacies (NADAC Benchmark)

What pharmacies pay to buy Abacavir, Dolutegravir, and Lamivudine: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.

How the Pharmacy Price Has Changed

Pick a strength to see how its price has changed since Nov 2023.

Strength

For brand-name Triumeq, the ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg tablet, pharmacies paid an average of $130.09 per tablet as of Nov 18, 2026, up 3.1% from $126.22 a year earlier.

What pharmacies pay now
$130.09
per tablet, as of Nov 18, 2026
Last 4 weeks
No change
from $130.08 on Oct 21, 2026
Last 12 months
Up 3.1%
from $126.22 on Nov 19, 2025
Lowest and highest since Nov 2023
$114.51 to $130.13
per tablet

Each step is one weekly survey. Arrow keys on the chart move week by week.
See the numbers, month by month
Triumeq ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg tablet: the average pharmacy price per tablet, the last survey of each month
MonthPharmacy price
Nov 2026$130.09
Oct 2026$130.08
Sep 2026$130.01
Aug 2026$130.13
Jul 2026$130.13
Jun 2026$130.11
May 2026$130.12
Apr 2026$130.01
Mar 2026$130.01
Feb 2026$130.01
Jan 2026$130.01
Dec 2025$126.22
Nov 2025$126.22
Oct 2025$126.33
Sep 2025$126.10
Aug 2025$126.14
Jul 2025$126.10
Jun 2025$126.11
May 2025$126.01
Apr 2025$126.00
Mar 2025$126.00
Feb 2025$126.00
Jan 2025$126.00
Dec 2024$121.16
Nov 2024$121.14
Oct 2024$121.18
Sep 2024$121.16
Aug 2024$121.16
Jul 2024$121.13
Jun 2024$121.13
May 2024$121.12
Apr 2024$121.31
Mar 2024$121.31
Feb 2024$121.31
Jan 2024$121.31
Dec 2023$114.51
Nov 2023$114.51
FormStrengthVersion What pharmacies pay
Tablet · Oral ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg Triumeq (brand) $130.09 per tablet NDC details & price history
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.

Abacavir, Dolutegravir, and Lamivudine Brand Names

Abacavir, Dolutegravir, and Lamivudine has 2 brand names on record: Triumeq and Triumeq PD. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Triumeq 2014 Triumeq PD 2022

Who Makes Abacavir, Dolutegravir, and Lamivudine: Manufacturers and Labelers

One company lists Abacavir, Dolutegravir, and Lamivudine products with the FDA. By number of product records, the largest are ViiV Healthcare Company. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

ViiV Healthcare Company 2

Sources for This Abacavir, Dolutegravir, and Lamivudine Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jul 8, 2024, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Abacavir, Dolutegravir, and Lamivudine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
2
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
ViiV Healthcare Company
Linked label effective
Jul 8, 2024
Composite sections available
22
Linked SPL Set ID
2997739a-aa91-42aa-a206-a70e2db7b84f
Linked SPL Document ID
4018a8c7-db0d-481e-b50a-a469ba32ec4b
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. ViiV Healthcare Company is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →